放疗联合吉西他滨及顺铂放化疗对Ⅲ期非小细胞肺癌的疗效评价

Efficacy Evaluation of Radiotherapy Combined with Gemcitabine and Cisplatin in the Treatment of Stage III Non-small Cell Lung Cancer

目的研究分析对Ⅲ期非小细胞肺癌(NSCLC)患者施予放疗联合吉西他滨、顺铂放化疗的价值及效果。方法回顾性分析该院2015年1月—2018年6月收治的86例Ⅲ期NSCLC患者的资料,将其中接受放疗联合吉西他滨、顺铂序贯放化疗的43例作为A组,另外接受放疗联合吉西他滨、顺铂同步放化疗的43例作为B组,观察比较其CD44V6与血管内皮生长因子(VEGF)、治疗疗效。结果 B组患者的CD44V6(292.45±75.49)μg/L与VEGF(144.65±65.87)pg/mL、治疗疗效97.67%好于A组患者(374.94±81.80)μg/L、(189.98±56.56)pg/mL、83.72%(t=4.859 6,3.423 7,χ~2=4.961 5,P<0.05)。结论放疗联合吉西他滨、顺铂同步放化疗在运用到对Ⅲ期NSCLC患者施予治疗后,其治疗的成效对比序贯放化疗来说更为突出,值得全方位推行与运用。

Objective To study the value and effect of radiotherapy combined with gemcitabine and cisplatin in patients with stage Ⅲ non-small cell lung cancer(NSCLC). Methods A retrospective analysis of 86 patients with stage Ⅲ NSCLC who were admitted to our hospital from January 2015 to June 2018, and 43 patients who received radiotherapy combined with gemcitabine and cisplatin sequential chemoradio therapy were included in group A. Fortythree patients with gemcitabine and cisplatin concurrent chemoradio therapy were enrolled in the group B, and their CD44 V6 and vascular endothelial growth factor(VEGF) were compared. Results The patients in group B had CD44 V6(292.45±75.49)μg/L and VEGF(144.65±65.87)pg/mL, and the therapeutic effect was 97.67% better than group A(374.94±81.80)μg/L,(189.98±56.56)pg/mL, 83.72%(t=4.859 6,3.423 7,χ^2=4.961 5,P<0.05). Conclusion Radiotherapy combined with gemcitabine and cisplatin in the treatment of patients with stage Ⅲ NSCLC after chemotherapy is more effective than sequential chemotherapy and radiotherapy. It is worthy of full implementation and application.